DCA114273: A Study Comparing Denosumab With Zoledronic Acid in Subjects of Asian Ancestry With Bone Metastases From Solid Tumors

Trial Profile

DCA114273: A Study Comparing Denosumab With Zoledronic Acid in Subjects of Asian Ancestry With Bone Metastases From Solid Tumors

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Bone metastases; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Primary endpoint has been met. (Percent change from Baseline in the bone turnover marker (BTM) uNTx/uCr), as per Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top